Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus

(2017) Sam Illingworth et al.   Molecular Therapy-Oncolytics

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators

(2017) Arthur Dyer et al.   Molecular Therapy-Oncolytics

Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes

(2017) Nalini Marino et al.   PLoS One

Oncolytic viruses: finally delivering

(2016) Leonard W Seymour et al.   BRITISH JOURNAL OF CANCER

Roles of regulatory T cells in cancer immunity

(2016) Yoshiko Takeuchi et al.   INTERNATIONAL IMMUNOLOGY

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth

(2016) Alison Tedcastle et al.   MOLECULAR THERAPY

Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis

(2015) L De Smedt et al.   BRITISH JOURNAL OF CANCER

Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy

(2015) J. J. Rojas et al.   CLINICAL CANCER RESEARCH

In-situ tumor vaccination: Bringing the fight to the tumor

(2015) Robert H Pierce et al.   Human Vaccines & Immunotherapeutics

Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors

(2014) V. Roulstone et al.   CLINICAL CANCER RESEARCH

Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood

(2014) Y Di et al.   GENE THERAPY

CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy

(2014) Christine E Engeland et al.   MOLECULAR THERAPY

Oncolytic Viruses as Anticancer Vaccines

(2014) Norman Woller et al.   Frontiers in Oncology

Field cancerization in the colon: a role for aberrant DNA methylation?

(2014) Y. Luo et al.   Gastroenterology Report

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

How Numbers, Nature, and Immune Status of Foxp3+ Regulatory T-Cells Shape the Early Immunological Events in Tumor Development

(2013) Guillaume Darrasse-Jèze et al.   Frontiers in Immunology

Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma

(2012) Evanthia Galanis et al.   MOLECULAR THERAPY

Crosstalk Between Immune Cell and Oncolytic Vaccinia Therapy Enhances Tumor Trafficking and Antitumor Effects

(2012) Padma Sampath et al.   MOLECULAR THERAPY

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

(2011) Caroline J. Breitbach et al.   NATURE

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

(2010) C. Comins et al.   CLINICAL CANCER RESEARCH

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1

(2009) R. C. Carlisle et al.   BLOOD

In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer

(2009) M Bauzon et al.   GENE THERAPY

Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus

(2009) Konstantin Doronin et al.   HUMAN GENE THERAPY

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

(2008) L. Vidal et al.   CLINICAL CANCER RESEARCH

Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer

(2008) Irene Kuhn et al.   PLoS One